SCHEMBL5363550

SCHEMBL5363550

CCOc1cccc(C=C2C(=O)Nc3ccc(CCCl)cc32)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.49
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MDM2 Q00987 3/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 1/20 0.42
KDR P35968 1/20 0.40
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
PDGFRB P09619 1/20 0.39
MAP3K7 O43318 1/20 0.39
TAB1 Q15750 1/20 0.39
GSK3B P49841 1/20 0.39
LRRK2 Q5S007 1/20 0.39
DHFR P00374 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359526 0.90 NPC1 (0.51) MEN1KMT2AMDM2GAANPC1
SCHEMBL7137229 0.84 MAP3K7 (0.50) MEN1KMT2AKDRPDGFRBMAP3K7
SCHEMBL7135629 0.84 IGF1R (0.53) IGF1RMEN1KMT2AMDM2ALDH1A1
SCHEMBL5366299 0.83 LRRK2 (0.53) MEN1KMT2ANPC1EGFRERBB2
SCHEMBL16442336 0.82 NPC1 (0.62) IGF1RMEN1KMT2AMDM2ALDH1A1
SCHEMBL7135678 0.81 NPC1 (0.65) MEN1KMT2AMDM2ALDH1A1MAPT
SCHEMBL5367320 0.81 MEN1 (0.54) MEN1KMT2AALDH1A1GAAMAPT
SCHEMBL5368521 0.79 KMT2A (0.60) MEN1KMT2AMDM2ALDH1A1MAPT
SCHEMBL5377083 0.79 SYK (0.50) IGF1RMEN1KMT2AALDH1A1GAA
SCHEMBL5374178 0.79 MAP3K7 (0.48) MEN1KMT2AMDM2KDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
US-6506763-B2 Useful in prevention and treatment of protein kinase related disorders such as cancer SUGEN, INC. 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK IGF1R 90/4885MEN1 3855/4885KMT2A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.